by an impairment of specific antibody production and a decrease in all or selected Ig isotypes. Abnormalities at the level of the B cells, T cells, and antigen-presenting cells have been described. In the present study, we have focused our attention on T-cell activation in CVID. T cells from 15 of 24 patients failed to respond to recall antigens (eg, tetanus toxoid, Escherichia coir). Of these 15 patients, 11 were studied in detail and showed significantly decreased T-cell Proliferative responses and/or decreased interleukin-2 and interferon-y production on T-cell receptor-mediated stimulation with recall antigens and superantigens (staphylococcal enterotoxins [SEI); however, T-cell response to mitogens (anti-OMMON VARIABLE immunodeficiency (CVID) is characterized by heterogeneity in the clinical manifestations of the disease as well as in the underlying mechanisms leading to immunodeficiency. An impairment in specific antibody production and a decrease in all or some Ig isotypes are the characteristic features, and defects in B-cell differentiation andor antibody secretion are common."3 Abnormal distribution of T-cell subsets has been shown in some CVID patients with an increase in the number of CD8+ cells>5 and multiple immunological abnormalities including functional T-cell defects such as abnormal helper function and increased T-cell suppressor activity have been described in these patients.' Reduced production of lymphokines in response to stimulation with mitogens such as anti-CD3 monoclonal antibodies (MoAbs) and phytohemagglutinin (PHA) have also been rep~rted.'~'~ In prior studies, we had investigated T-cell activation in response to recall antigens (Escherichia coli, tetanus toxoid) in three CVID patients and showed that proliferative responses as well as interleukin-2 (IL-2) and interferon-y (IFN-7) mRNA levels were significantly reduced after antigen stimulation, whereas T cells responded normally to anti-CD3 (OKT3) and mitogen." These results pointed to a defect in T-cell activation after triggering of the T-cell receptor (TCR).
OMMON VARIABLE immunodeficiency (CVID) is
characterized by heterogeneity in the clinical manifestations of the disease as well as in the underlying mechanisms leading to immunodeficiency. An impairment in specific antibody production and a decrease in all or some Ig isotypes are the characteristic features, and defects in B-cell differentiation andor antibody secretion are common."3 Abnormal distribution of T-cell subsets has been shown in some CVID patients with an increase in the number of CD8+ cells>5 and multiple immunological abnormalities including functional T-cell defects such as abnormal helper function and increased T-cell suppressor activity have been described in these patients. ' Reduced production of lymphokines in response to stimulation with mitogens such as anti-CD3 monoclonal antibodies (MoAbs) and phytohemagglutinin (PHA) have also been rep~rted.'~'~ In prior studies, we had investigated T-cell activation in response to recall antigens (Escherichia coli, tetanus toxoid) in three CVID patients and showed that proliferative responses as well as interleukin-2 (IL-2) and interferon-y (IFN-7) mRNA levels were significantly reduced after antigen stimulation, whereas T cells responded normally to anti-CD3 (OKT3) and mitogen." These results pointed to a defect in T-cell activation after triggering of the T-cell receptor (TCR).
In the present study, we investigated whether the defect described is limited to rare cases or is expressed in a large subgroup of CVID patients. To further characterize the defect, we addressed the question of whether the impaired CD3 monoclonal antibody, phytohemagglutinin) was normal. The defect in interleukin-2 and interferon-y release on tetanus toxoid stimulation could also be documented in purified CD4 T cells of the patients and was present in patients with high and normal CD8 counts alike. Furthermore, patients' T cells failed to mount a significant elevation in free intracellular calcium E a + + flux) in response to superantigen, whereas the response to phorbol myristate acetate and ionomycin, bypassing receptor-mediated signaling, was unimpaired. These results indicate a defect in the early phase of T-cell activation after triggering of the T-cell receptor in a significant subgroup of CVID patients. 0 1994 by The American Society of Hematology.
response to recall antigen is caused by defective recognition of the antigen by the TCR or by a defect in the transduction of transmembrane signals leading to impaired generation of second messengers after TCR triggering. The results obtained show that the T-cell activation defect is detectable in a relevant subset of CVID patients and that the defect is observed after triggering of the TCR with antigen, superantigen, or anti-TCR MoAb. In addition, TCR-mediated stimulation with superantigens failed to induce a rapid and sustained increase in levels of intracellular free Ca++ in patients' lymphocytes, whereas the response to phorbol myristate acetate (PMA) and ionomycin (IM) was normal. These results suggest a defect in the early phase of T-cell activation after triggering of the TCR before the generation of intracellular free Ca++ and before protein kinase C activation.
MATERIALS AND METHODS

Patients.
At the time of the study, 24 patients with CVID as defined by the World Health Organization classification of primary immunodeficiencies" were followed up by our immunology division. The patients had a history of recurrent bacterial infections of the upper and lower respiratory tract and reduced or absent serum IgG, IgA, and IgM levels. In 9 of the 24 patients, the T-cell response to recall antigen ( E coli or tetanus toxoid) was comparable with the response in healthy individuals, and 2 of these 9 patients had low numbers of B cells in their peripheral blood. Fifteen patients had T lymphocytes incapable of responding to recall antigen presented by autologous antigen-presenting cells (APCs). One patient was shown to have a defect in APCs." Three further patients were excluded from the study because of severe concomitant disease (lymphoma, alcoholic cirrhosis of the liver, and eosinophilic gastroenteritis with severe gastrointestinal loss of protein). The remaining I1 patients, S men and 6 women ranging in age from 17 to 50 years, were enrolled in the study after informed consent had been obtained. These 1 1 patients showed hypogammaglobulinemia or agammaglobulinemia with a decrease in all Ig isotypes and consistently impaired production of specific antibodies in the presence of normal numbers of B cells, as well as impaired ability of their T cells to respond to recall antigens (eg, tetanus toxoid, E coli). During the course of this study, all patients were on regular gammaglobulin replacement therapy (7 patients, intravenous administration of 400 mg IgGkg body weight per month; 4 patients, intramuscular administration of 100 mg Igkg body weight per month). All patients had received tetanus toxoid vaccination or boosters within the last 6 to 12 months before the study. At the time of evaluation, none of the patients was [Leu 191) were within the normal range. Five patients had normal CD8' counts (32% ? 9% of lymphocytes; mean t SD), whereas high CD8 counts could be detected in 6 patients (52% ? 12% of lymphocytes). Healthy age-matched volunteers were investigated in parallel and served as controls. The vaccination history of the controls was comparable with that of the patients.
Isolation of mononuclear cells (MNCs) and preparation of a Tenriched lymphocyte population. PBMNCs were isolated from heparinized whole blood (7.5 IU/mL of preservative-free heparin) by buoyant density gradient centrifugation.'6 Monocytes were prepared by adherence to plastic surfaces as described previously." Adherent cells were washed several times and removed gently with a rubber policeman. Cell purity was 80% to 90% monocytes, as defined by flow cytometry with a CD14 MoAb. Nonadherent cells were removed and fractionated into T-enriched cells (>95% CD2+ and >90% CD3+ cells) and non-T cells by rosetting with sheep erythrocytes treated with 2-aminoethylisothiouronium bromide (Sigma Chemicals, St Louis, MO) as described earlier."
Lymphocyte proliferation. Triplicate cultures containing adherence-purified monocytes (1 X 104/well) and T-enriched cells ( Induction and measurement of IL-2 and IFN-y in T-cell supernatants. Cultures of macrophages (l X 105/mL) and T-enriched cells (1 X 106/mL) were set up in 24-well tissue culture plates and activated using the stimuli and culture media as described above. Culture supernatants were removed after 24 or 72 hours of incubation, were sterile-filtered, and were analyzed for their cytokine content. The IL-2 concentration was determined using the murine cytotoxic lymphoid cell line CTLL-2 as described earlier.13 Concentrations of IFN--y in culture supernatants were determined using a commercial enzyme-linked immunosorbent assay (ELISA) kit (IFN--y Medgenix, Brussels, Belgium). IFN-y concentrations were calculated using a standard curve derived by linear regression of the log-transformed concentrations of the cytokine standards supplied with the ELISA kits versus the respective log-transformed ELISA-optical density (OD) values.
Separation of CD4+ T lymphocytes. CD4+ T cells were isolated by negative magnetic immunoselection. In brief, MNC were adhered to plastic surfaces to remove monocytes; nonadherent cells were E+-rosetted and the E' cells were incubated with saturating concentrations of CD8 MoAb (Leu 2a) and CD56 MoAb (Leu 19; Becton Dickinson, used at a final concentration of 2.5 pg/l X lo7 cells) for 30 minutes at 4°C under continuous rotation. Cells were washed twice, mixed with sheep antimouse IgG-coated beads (Dynabeads M450; at a final concentration of 1 X IO' beads11 X IO' cells) and incubated for another 30 minutes at 4°C under continuous rotation. Cells that were reactive with the two MoAbs and thus bound to the magnetic beads were removed with a powerful permanent cobaltsumarium magnet (HPC-I; Dynal). The remaining cells were collected, washed twice, and analyzed by flow cytometry. Cell purity was 90% to 95% CD4' cells.
Assay of intracellular free Ca++ Concentration. The increase in intracellular free Cat+ observed after stimulation of T cells was measured by flow cytometry. In brief, T-enriched cells (2 X lo6/ mL) were loaded with two fluorochromes, the Ca++-sensitive dye mL), and anti-IgM-coated beads were used at a final dilution of l X lo6 beaddl X lob MNCs. PWM and SAC were used at a final dilution of 1500 and 1:5000, respectively, and rIL-2 was used at 100 U/mL. Culture supernatants were harvested on day 7, were sterile-filtered, and were assayed using an Ig isotype-specific ELISA as described earlier.'.'
Statistics. For statistical evaluation of the difference between patients and controls, the nonparametric Mann-Whitney V test (onetailed) or the Student's t-test for unpaired samples was used. Multivariate analysis of more than two study groups was calculated using the Kruskal-Wallis one-way ANOVA by ranks to confirm a significant difference between two study groups. A difference was considered to be statistically significant at a level of P < .05.
RESULTS
Impaired T-cell response to recall antigen is expressed in a relevant subset of CVID patients. At the time of the study, 24 patients with CVID were followed up by our immunology division. As shown in Fig I, all 24 patients responded to PHA with substantial proliferation. In contrast, analysis of the response to recall antigen (tetanus toxoid or E coli) showed two distinct populations. Of the 24 patients recently (within 1 year before the study) vaccinated with tetanus toxoid, 15 showed an impairment of tetanus toxoid-induced T-cell activation in the presence of functionally intact autologous macrophages (Fig 1) . T cells of these 15 patients were also unresponsive to stimulation with E coli (data not shown). The remaining 9 patients responded normally to tetanus toxoid (Fig 1) or E coli (data not shown).
FISCHER ET AL
The defect in T-cell activation results in impaired IL-2 and IFM-y release and can be observed after triggering of the TCR by dzfferent stimuli. Further studies were designed to characterize the T-cell activation defect observed in the patients unresponsive to recall antigens. Superantigens such as SEs are an appropriate tool for studying TCR-mediated T-cell activation. Because they do not have to be processed by APCs to be presented in context with the major histocompatibility complex class I1 molecule, they stimulate the T cells by binding to the TCR-V@ chain outside the recognition site for antigen and activate between 1 in 5 and 1 in 20 PB T cells. In contrast, conventional antigens stimulate fewer than 1 in 10,000 PB T cells. Although patients' T cells expressed comparable levels of Vp2, Vp3, VP5a and c, VP6a, Vp8, VP8a, Vp12a, Vp13, Vp17. and V019 (data not shown), their proliferative response as well as IL-2 and I F N -y production after stimulation with SEA, SEC3, or SED (1 ng/mL) were significantly impaired (Fig 2) . Furthermore, patients' T cells released significantly reduced amounts of IL-2 and IFN-y when stimulated with an MoAb specific for the constant region of the TCR &chain (BMA-03 1 ; see Fig   2) . When the patients' T cells were stimulated via CD3, proliferation and IL-2 release were comparable with that of the controls (Fig 2) , and IFN-y production was slightly (but not statistically significantly) decreased ( P = .096 as compared with that of the controls; see Fig 2) . Levels of T-cell proliferative responses and IL-2 and IFN-y production after stimulation with PHA were comparable in patients and controls (for statistical comparison between patients and controls see legend of Fig 2) .
The defect in TCR-mediated T-cell activation can be detected in purijied CD4' T cells and cannot be corrected by exogenous rIL-2. Because increased numbers of CD8' cells have been described to be associated with impaired Tcell function in CVID?5 we examined whether the impairment of T-cell activation observed in our patients correlated with the levels of CD8' cells in the PB. As shown in Table  1 , antigen-induced T-cell proliferation as well as IL-2 and IFN-y release were equally depressed in patients with high numbers of CD8' T cells (ie, >40% CD8' lymphocytes) as well as in those with normal numbers of CD8' T cells. To assure that the defect observed was not caused by suppression by CD8' cells, purified CD4+ cells (purity between 90% and 95%) were prepared by depletion of CD8' and CD56+ cells from the T-enriched population. Patients' CD4-enriched cells as well as their T cells responded normally to PHA stimulation (Fig 3) or anti-CD3 MoAb stimulation (controls [n = 61: 'H-thymidine incorporation (dpm), 84127 2 54962 and IFN-y release, 157 2 149 U/mL; patients [n = 71: 'H-thymidine incorporation (dpm), 108944 ? 40176 and IFN-y release, 175 2 82 U/mL; mean t SD). In contrast, purified CD4+ T cells of the patients were unable to respond with substantial proliferation and with IL-2 and IFN-y production to the recall antigen tetanus toxoid. Addition of exogenous rIL-2 to the patients' CD4' T cells significantly increased antigen-induced T-cell proliferation and IFN-y release as compared with tetanus toxoid ( P < ,005) or IL-2 ( P < .01) alone, but proliferative responses and IFNy release in the patients were still significantly lower than that in the controls (Fig 3) . SEs (SEA, SEC3, and SED in a final concentration of 1 nglmL) as described in Materials and Methods. Supernatants from PHA-, anti-CDg-, anti-TCR-, and superantigen-stimulated cultures were harvested 24 hours after stimulation, whereas supernatants from antigen-driven cultures were collected after 72 hours. The supernatants wera assayed for IL-2 and IFN-y as described in Materials and Methods. sH-thymidine incorporation was determined after 3 days of culture for PHA and anti-CD3 MoAb, after 5 days of culture for superantigen and anti-TCR MoAb, and after 7 days of culture for antigen, as described in Materials and Methods. Values represent mean f SD; statistically significant differences between patients and controls are marked with an asterisk. Statistical comparison between patients and controls is as follows: for PHA proliferation, P = .112; IL-2, P = .33; IFN-y, P = .308; for anti-CD3 M o b prolieration, P = ,179; L-2, P = .5; IFN-y, P = .M; for anti-TCR M o b proliieration, P = .311; IL-2, P = .0083; IFN-y, P .OO01; for Ter. tox.: proliferation, P < .Mol; IL-2, P ,0001; IFN-y, P .0001; for SEA proliferation, P = .0015; IL-2, P = .00029; IFN-y, P = .01; for SEC3: proliferation, P = .0021; IL-2, P = .0003; IFN-y, P = . O W ; and for SED: proliferation. P = .0022; IL-2, P = .00045, IFN-y, P = .03. (U) Controls (n = IO); (B) patients (n = 10).
Impaired intracellular free Cat+ in patients' T cells after triggering of the TCR by superantigens. A cocktail of seven different superantigens as described in Materials and
Methods was used to examine the increase in intracellular free Ca++ after triggering of the TCR. T cells from healthy controls responded with a significant Cat+ flux to triggering of the TCR by superantigen presented on the surface of autologous monocytes. In contrast, patients' T cells were significantly (P < .001) depressed in their capacity to mount an increase in intracellular free Ca++ after triggering with superantigens (Fig 4) . Stimulation of the same cells with the combination of PMA + IM, which thus bypassed receptormediated signal mechanisms by direct activation of diacylglycerol (DAG) and mobilization of free Ca' from intracellular and extracellular stores, resulted in a significant Ca++ flux in the patients' cells to levels that were comparable with that of the controls (Fig 4) . These results indicate a defect in the early phase of T-cell activation after triggering via the TCR, before the generation of the second messengers DAG and inositoltriphosphate (IP3).
B cells of CVID patients produce IgM, but not &G, after in vitro stimulation. PB B cells in patients whose T cells were unresponsive to recall antigen were normal in numbers (data not shown), but Ig secretion in vitro was impaired. Although stimulation of PB lymphocytes with P M , SAC, or anti-IgM plus rIL-2 resuited in levels of IgM secretion that were comparable with that of controls, none of the stimulants induced IgG release in the patients' B cells ( Table 2) .
DISCUSSION
The results presented here confirm and extend our previous observation made in three patients with CVID by showing that T cell activation on triggering of the TCR is defective in a significant subset of CVID patients (15 of 24 patients). Furthermore, the results of the present study provide evidence that a major subgroup of CVID patients expresses a defect in the early phase of T-cell activation after triggering of the TCR.
Impaired T-cell activation, including defective 1L-2 production on activation with mitogenic lectins or anti-CD3, has been observed previously by several investigator^.^"' Sneller et al' described four patients with CVID whose T cocultivated and stimulated with tetanus toxoid (10 FISCHER ET AL Conflicting data have been reported with regard to the role of immunoregulatory abnormalities such as an increase in CD8' T cells in the impaired response of T cells to antigen in CVID patients. A report by Wright et a14 described 5 of 12 CVID patients with high CD8 counts who were anergic as determined by skin testing of delayed-type hypersensitivity (DTH) reaction, whereas, in the group of CVID patients with normal numbers of CD8 positive cells, only 1 of 15 patients was anergic to recall antigens. These data suggest that, in CVID patients with high levels of CD8' T cells, antigen unresponsiveness is more frequent than in CVID patients with normal numbers of CD8' T cells. Jaffe et allx reported that CD4' T-cell function (the principal T-cell subset responding to antigen) of patients with high numbers of CD8' T cells was unimpaired.
The defect in T-cell antigen responsiveness observed in the subgroup of CVID patients we studied was expressed both in patients with high and with normal CD8 counts, and no correlation could be found between CD8 counts and tetanus toxoid-specific T-cell proliferation (linear regression analysis; data not shown). Purified CD4' cells expressed the T-cell activation defect both in the absence or presence of CD8' T cells alike. Therefore, it appears unlikely that the defect described is caused by immunoregulatory abnormalities such as an increase in CD8' cells leading to excessive suppression at the T-cell level.
Defective ligand recognition by TCR is not likely to be the only explanation for the impaired response to antigen. The combination of antigen and exogenously added rIL-2 induced significantly higher proliferative response and lymphokine secretion in the patients' T cells than did either antigen or IL-2 alone. Furthermore, antigenic stimulation induced normal production of IL-2 receptor, IL-3, and IL-4 mRNA transcripts in these patients' T lymphocytes in the were loaded with Fluo-3 (1 pmol) and Snarf-l (0.2 pmol) and were subsequently stimulated with autologous monocytes (2 x 106/mL) that had been pulsed with a cocktail of different superantigens (final SE concentrations: SEA, 5 pg/mL; SEB, 10 pg/mL; SECl, 10 pg/mL; SEC2.5 pg/mL; SE=, 5 pg/ml; SED, 5 pg/mL; SEE, 1 pg/mLI. Changes in the levels of intracellular free Ca+* in patients' and controls' T-enriched lymphocytes were determined using a cytofluorograph as described in Materials and Methods. Stimulation with a combination of PMA (1 pg/ mL) and IM (5 pg/mL) resulted in a maximum increase in intracellular free CB++ and served as a positive control in these experiments. Results are depkted as relative intracellular Ca*+ increase (F111F13' ; mean ? SD) calculated as described in Materials and Methods. The relative intracellular Ca++ increase observed after addition of unpulsed autologous monocytes to patients' or controls' T cells did not exceed 1.10. Statistically significant differences between patients and controls (Student's t-test, P < .001) are marked with an asterisk. presence of impaired IL-2 and IFN-.)I gene expression (Hauber et al, manuscript submitted), clearly indicating that the antigen had been recognized by the T cell and delivered a signal. In addition, T-cell response to superantigen stimulation was impaired. Superantigens stimulate the T cell by binding to the TCR-VP chain apart from the antigen binding site. No evidence for narrowing of the TCR-VP repertoire could be found, because T cells of this group of patients with CVID expressed comparable levels of VP2, VP3, VPSa and c, VP6a, VPS, VpSa, VP12a, VP13, VP17, and VP19 (data not shown), as has also been described by others." Even though binding of superantigen to the TCR has not been assessed directly, the normal expression of the TCR-VP repertoire makes impaired binding of superantigens unlikely. Finally, stimulation via the monomorphic region of the TCR with anti-TCR MoAb resulted in impaired T-cell activation as shown by significantly reduced cytokine release, whereas expression of the TCRa-P molecule on the T-cell surface was normal (data not shown). The reduced response to antigen, superantigen, and anti-TCR MoAb binding to distinct sites of the TCR points to defective TCR-mediated signaling and makes impaired ligand recognition unlikely.
Increasing experimental evidence points to the possibility that signaling events in T-cell activation on stimulation of the TClUCD3 complex might follow at least two different pathways.20.z' Examples of this dichotomy also come from experiments of nature. T cells of patients with Wiskott-Aldrich syndrome were shown to function normally when triggered with antigen but showed a defect in activation when triggered with a11ti-CD3.~~ T cells from our CVID patients could be activated normally on anti-CD3 triggering but could not be activated to express IL-2 after stimulation of the TCRa-P molecule. The possibility that T-cell activation by superantigen and by antigen follows different signal transduction pathways has been indicatedz3 but needs further clarification. The question of Ca++ mobilization in T cells after superantigen stimulation is controversial. Oyaizu et a1,24 when studying human T-cell lines and their response to superantigen, did not observe a significant Ca++ flux, whereas two groups using resting human T cells from the PB25*z6 were able to induce Ca++ flux on stimulation with superantigens. These discrepancies could be explained by differences in the cell population studied or the nature and concentration of the superantigen applied. It is feasible that superantigens applied at lower concentrations, as in the study by Oyaizu et al," may preferentially stimulate T-cell activation without
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From inducing measurable Ca++ flux. Our experiments followed the experimental design described by Fleischer et alZS and Chatila et alZ6 and confirm that, in resting PB T cells of healthy individuals, bacterial superantigens applied at microgram concentrations induce a measurable Ca++ flux. The patients' T cells were clearly deficient in mounting a Ca++ flux after superantigen stimulation in this system. Although it is unlikely, our results cannot rule out a delayed Ca++ response after triggering of the TCR with superantigen in the patients. The combination of PMA and I M , agents that bypass receptor-mediated signal mechanisms, was shown to induce an appropriate and immediate increase in cytosolic free Ca++ concentration in the patients' lymphocytes and also triggered normal proliferation and cytokine release (data not shown). Therefore, it appears likely that the impairment in T-cell activation observed in our patients is caused by a defect in early signaling events after triggering of the TCR. Although our results indicate that TCR-coupled generation of second messengers such as intracellular free Ca++ is defective in the patients, other TCR-coupled signaling pathways independent of Ca++ mobilization could also be impaired.
The impairment in T-cell activation found in this subset of CVID patients is not absolute. Although IL-2 mRNA and protein levels are decreased after TCR stimulation, possibly as a consequence of reduced Ca++ mobilization, other events triggered by TCR activation such as gene expression of IL-2 receptor, IL-3, and IL-4 are unimpaired (Hauber et al, manuscript submitted). This might be because of different signaling requirements, eg, different pathways and/or quantitative differences in the levels of second messengers proprincipally capable of producing IL-2 after triggering of surface receptors other than TCR (eg, mitogenic stimulation with PHA known to trigger both the TCWCD3 complex and CD2)29,"' or by stimuli that bypass surface receptor-mediated signaling (eg, PMA + IM).I3 dUced.Z0,21,27,28 Furthermore, T cells from these patients are A defect in antigen-induced T-cell activation leading to decreased lymphokine release can have several important implications for the pathogenesis of CVID. T cells act on isotype-uncommitted or naive B cells by signaling via CD40 and modulate switch mechanisms at the DNA level. In addition, T cells support the expansion of committed B cells that already have undergone Ig isotype switching."." IL-2 is a potent inducer of human B-cell proliferation and differentiation,'j and deficient production of IL-2 by T cells on antigenic stimulation may contribute to the B-cell abnormalities observed in these CVID patients. In addition, decreased IFNy production, whether primary or secondary to the decreased IL-2 release, may also have implications for B-cell differentiati0n.j' In agreement with this notion, patients with impaired TCR-mediated T-cell activation showed a rather uniform pattern with respect to B-cell numbers and function. B-cell numbers were normal, and the B cells secreted normal amounts of IgM in response to several stimuli (PWM, SAC, IgM + IL-2) but were unable to produce IgG. A defect in the production of specific antibodies is common to all patients with CVID. The impairment of TCR-mediated signaling leading to reduced IL-2 and IFN-y production is likely to contribute to the pathophysiology of the disease in a significant subset of these patients.
